Q&A Special Q&A with Gosia Trynka, Open Targets Experimental Science director We're delighted to have caught up with Gosia Trynka, our new Experimental Science director, for a very special Q&A on Open Targets science and more.
Open Targets Platform Open Targets Platform: release 20.02 is out We have a new release of the Open Targets Platform: new ... ... more targets, more evidence and associations.
Cancer An Open Targets Away Day with The Institute of Cancer Research Open Targets meets colleagues at the Institute of Cancer Research in London: potential collaboration ahead of us
ontology EFO3: A community-driven ontology to advance clinical discoveries In the 19.11 release of the Open Targets Platform, we moved from EFO2 to EFO3. Here we explore what the new disease ontology means to Open Targets.
Open Targets Platform Using ChEMBL for target identification and prioritisation Open Targets Q&A on the identification of cancer driver genes and their mechanism of action using intOGen. Using ChEMBL for target identification and prioritisation
Open Targets Platform Open Targets Platform: release 19.11 is out We have a new release of the Open Targets Platform: new EFO3, FDA pharmacovigilance data, new chemical probes, more targets, more evidence and associations.
Open Targets Platform From antibody to zinc finger: an A-Z of Open Targets As scientists discover our freely available resources, it’s time to take a closer look at the terms that matter to Open Targets. November is time for H.
Open Targets Platform Open Targets Platform: release 19.09 is out We have a new release of the Open Targets Platform: more target-disease associations, more chemical probes and target enabling packages, and updated Elasticsearch.
Open Targets From antibody to zinc finger: an A-Z of Open Targets As users discover our freely available resources, it’s time to take a closer look at the terms that matter to Open Targets. This time we have a double bill: F and G.
Open Targets Platform Open Targets Platform: release 19.06 is out We have a new release of the Open Targets Platform: more target safety information and new target-disease associations are some of the highlights in release 19.06.
Q&A Using CRISPR priority score to identify targets in cancer drug discovery Open Targets Q&A on the first set of CRISPR screen results in cancer for target identification and prioritisation in drug discovery.
Open Targets Platform Open Targets Platform: release 19.04 is out We have a new release of the Open Targets Platform: CRISPR-Cas9 data and target safety information are some of the highlights in release 19.04.
Open Targets From antibody to zinc finger: an A-Z of Open Targets As users discover our freely available resources, it’s time to take a closer look at the terms that matter to Open Targets. March is time for E.
Open Targets Platform Open Targets Platform: release 19.02 is out Our latest release of the Open Targets Platform is out. We have more targets, more diseases, more evidence, more associations, and fixed some bugs too.
Open Targets Platform From antibody to zinc finger: an A-Z of Open Targets As users discover our freely available resources, it’s time to take a closer look at the terms that matter to Open Targets. It's D-time.
Open Targets Platform Open Targets Platform: new release is out The latest release of the Open Targets Platform is out. We have more evidence, new targets, new diseases and new associations, plus data from Probe Miner.
Open Targets Platform Get to know the Reactome enhanced pathway visualisations Open Targets Q&A on the new Reactome pathway visualisations: scalable, interactive textbook-style diagrams in SVG format, freely downloadable and editable.
Europe PMC How Europe PMC can help you find associations between genes and diseases Open Targets Q&A on how you can stay up-to-date with the latest advances in drug discovery.
release notes The latest release of the Open Targets Platform is out! We have a new release of the Open Targets Platform. New data source for target-disease associations, new drug visualisations, cancer biomarkers, and more.
Open Targets Touring with Takeda Following Takeda joining Open Targets in December 2017, I set off to Takeda in the US and Japan for a series of workshops.
Open Targets Open Targets Platform: we have a new release The latest release of Open Targets Platform is out. We now have the cancer hallmarks, targeted association studies, a YouTube channel and much more.
release notes Open Targets Platform: our December release is out! The latest release of Open Targets Platform is out. We now have a dedicated page for drugs, mouse phenotypes mapped to human targets, and more cancer genes.
release notes Open Targets Platform: our latest release is out! We have just released the latest Open Targets Platform, release 17.09. Let's crunch some of the numbers before moving on to our highlights: targets diseases evidence associations 19,803 9,341 6,
Open Targets Platform What is new in the latest release of the Open Targets Platform? The latest version of our Open Targets Platform is out. We have more diseases, more evidence, more associations, more data sources, but fewer targets. If you wonder what and why, keep reading. Let's
Open Targets Translation, Translation, Translation Over the last 14 days, we have had two scientific meetings taking place right here on the Wellcome Genome Campus, the Translational Bioinformatics conference and the Translational Target Validation symposium. What did they
